{"entity":{"id":"treatment-effect-in-pathology","kind":"term","name":"Treatment effect in breast pathology","aka":["histological treatment effect","post-treatment tissue changes"],"tldr":"Treatment effect describes tissue changes after therapy, assessed separately from whether viable cancer remains in the examined breast and nodes.","summary":"Response-related changes and residual carcinoma answer different questions. Interpretation needs treatment history, mapped sampling and separate breast and nodal findings. Fibrosis is not automatically residual tumour size or proof of complete response.","asOf":"2026-11-10","links":[{"label":"CAP invasive breast resection protocol 4.11.0.0, June 2026","url":"https://www.cap.org/wp-content/uploads/2026/06/Breast.Invasive.Res_4.11.0.0.REL_CAPCP.pdf?download=true"},{"label":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.","url":"https://doi.org/10.1038/modpathol.2015.74"}],"tags":[],"related":["pcr","rcb","tumor-bed-cellularity","tnm-staging"],"cancers":["breast-cancer"],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["After preoperative therapy, fibrosis, necrosis, inflammation and histiocytic aggregates can be response-related tissue changes. Residual viable carcinoma is a separate morphological assessment, not a culture test of every cell. Response changes and residual cancer can coexist; scarring alone does not establish that no cancer remains. Fibrosis means collagen-rich scarring, necrosis means dead tissue and histiocytes are tissue macrophages.","CAP 4.11 describes the RCB breast span as the two-dimensional extent of residual invasive carcinoma, excluding DCIS from the span. The MD Anderson microscopy protocol instead starts with the gross tumour bed, revises its boundaries microscopically and estimates invasive plus in situ cancer area in that bed, using the largest bed for multicentric disease. State the protocol and denominator rather than merging these wordings. The largest contiguous residual invasive focus without adjacent treatment fibrosis supplies ypT; the gross scar, that focus and an RCB bed are different measurements. For ypN, adjacent treatment fibrosis is likewise excluded from the contiguous staging dimension; RCB nodal measurement has its own rule.","Assessment connects pretreatment location, imaging or marker information, gross mapping, a sampling plan and microscopy. Sparse, scattered residual foci make arbitrary-section interpretation unreliable. A broad scar can contain residual invasive cancer without the whole scar being solid cancer.","Breast and node response are reported separately. Nodal scarring or histiocytic aggregates without residual cancer can be consistent with prior treated involvement, but do not independently establish biopsy-proven baseline metastasis. Prior biopsy or other injury can also produce repair changes; a scar alone cannot establish a drug-specific effect.","RCB is not validated for neoadjuvant endocrine treatment; CAP advises against reporting a score/class in that setting even when individual residual measurements are recorded. Combined pCR requires its stated breast-and-node definition and appropriate specimens, may permit DCIS and does not establish whole-body eradication. Preserve the pretreatment record alongside residual findings."],"category":"Clinic basics"},"route":"/terms/treatment-effect-in-pathology/","neighbours":{"term":[{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/"},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/"},{"id":"tumor-bed-cellularity","kind":"term","name":"Tumour-bed cellularity","route":"/terms/tumor-bed-cellularity/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}]}}